All Tech Innovators

Wei Li

13 results

(0.04 seconds)

Novel Treatment for Neuroblastoma and Ewing Sarcoma

07186

Fully human GFRA2-targeting antibodies enable potential NB/ES immunotherapies (ADCs, CAR-T, bispecifics) with reduced off-target effects.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Glioblastoma
Tags: Life Science
Lead Inventor: Wei Li
Department: Med-Medicine
All Tech Innovators: Sharon Diskin
Amber Hamilton
Wei Li
Date Submitted: 2025-05-14

Next-Generation Long-Lasting Soluble CD4-D1 Domains as HIV Entry Inhibitors

06603

Engineered soluble CD4-D1 variant offers long-lasting HIV entry inhibition with enhanced stability, MHC II avoidance, and broad neutralization.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Bispecific
Therapeutic Areas: Infectious Disease
Therapeutic Indications: HIV
Lead Inventor: Wei Li
Department: Med-Medicine
All Tech Innovators: Xiaojie Chu
Jana Lynn Jacobs
Wei Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2024-01-08
Collections: Women's & Reproductive Health

Fully Human Fab and VH Antibody Binding to PLA2G7

06870

Fully human antibodies block PLA2G7 to reduce inflammation, with potential anti-aging and cancer therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Bispecific
Therapeutic Areas: Oncology
Cardiovascular
Therapeutic Indications: Stroke
Atherosclerotic disease
Tags: Aging
Lead Inventor: Seungmin Shin
Department: Med-Medicine
All Tech Innovators: Dimiter Stanchev Dimitrov
Wei Li
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2024-09-09
Collections: Cardiometabolic

Novel Llama Nanobody to Treat HIV-1

06827

Humanized llama nanobody 4E2 neutralizes diverse HIV-1 strains, offering a potential long-term, low-immunogenic therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Immunology
Infectious Disease
Therapeutic Indications: HIV
Tags: Drug Discovery - Target
Life Science
Lead Inventor: Wei Li
Department: Med-Medicine
All Tech Innovators: Zhiwei Feng
Margaret Grace Hines
Wei Li
Date Submitted: 2024-07-26
Collections: Women's & Reproductive Health
Healthcare AI

Human Monoclonal Antibodies against SARS-CoV-2

05259

Neutralizing human monoclonal antibodies target SARS-CoV-2 spike RBD, blocking entry or directing infected-cell killing.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Covid-19
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Chuan Chen
Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2020-02-26

uPAR-Targeting Human Antibody for Treating Cancer and Fibrotic Diseases

06240

uPAR-targeting human VH antibodies offer potent, versatile cancer/fibrosis therapy with VH-Fc fusion for enhanced stability and penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Hepatology
Oncology
Therapeutic Indications: Gastric Cancer / Intestinal Adenocarcinoma
Melanoma
Pancreatic adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Xiaojie Chu
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-12-06
Collections: Cardiometabolic
Women's & Reproductive Health

Fully Human Anti-FLT3 (CD135) Antibodies for Leukemia

05621

Fully human anti-FLT3 antibodies discovered for broad cancer targets; potential for enhanced tumor penetration and safer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Terry Fry
Wei Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-02-18
Collections: Women's & Reproductive Health

Immunotherapy for Neuroblastoma and Ewing Sarcoma

07259

GFRA2-targeted, fully humanized antibodies enable precise neuroblastoma/Ewing sarcoma therapies (CAR-T, ADCs) with potential imaging uses.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Neuroblastoma
Glioblastoma
Tags: Life Science
Lead Inventor: Wei Li
Department: Med-Medicine
All Tech Innovators: Sharon Diskin
Amber Hamilton
Michelle Keyel
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2025-07-29

In Vivo–Validated Anti-CD276 (B7-H3) VH-Domain/Fab Antibodies

04890

Novel fully human VH-domain and Fab antibodies target CD276 (B7-H3) for versatile solid-tumor immunotherapy and enhanced penetration.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Bispecific
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Wei Li
John W. Mellors
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-02-11

PSMA with Multiple Single-Chain and Domain Binders Treats Prostate Cancer

05717

PSMA-targeting small VH-domain antibodies enable potent ADC/ADCC/CAR-T therapies with enhanced tumor penetration and distinct epitopes.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Prostate cancer / adenocarcinoma
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-06-09

Identification of Fully Human anti-PSCA Antibodies

05676

Fully human anti-PSCA antibodies enable targeted therapy and ADCs for PSCA-expressing prostate and other solid tumors.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Pancreatic adenocarcinoma
Renal cell carcinoma (RCC)
Urothelial carcinoma (Bladder cancer)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Dontcho V. Jelev
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-04-21

Fully Human Fabs to CD22 (bCAT1)

04874

Fully human anti-CD22 D7 binders enable CAR-T and ADCs for B-cell cancers, targeting proximal epitopes for enhanced efficacy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Lymphoma
Leukemia
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-01-27

Human Antibodies Identified as Brain Cancer Immunotherapy Targets

05700

Eight human antibody domains target protogenin to curb pediatric medulloblastoma growth, offering promising brain-cancer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Therapeutic Indications: Brain cancer - Other
Diffuse intrinsic pontine gliomas (DIPG)
Medulloblastoma
Tags: Pediatrics
Rare disease
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Chuan Chen
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2021-05-25
Collections: Cell & Gene Therapy